Direkt zum Inhalt
Merck
  • Candida albicans prosthetic hip infection in elderly patients: is fluconazole monotherapy an option?

Candida albicans prosthetic hip infection in elderly patients: is fluconazole monotherapy an option?

Scandinavian journal of infectious diseases (2010-01-09)
Theodoros Kelesidis, Sotirios Tsiodras
ZUSAMMENFASSUNG

The increasing numbers of joint arthroplasties being undertaken, and the increase in patients with systemic illnesses undergoing the procedure, have contributed to a continuing increase in prosthetic joint infections. Candida prosthetic joint infection is a rare clinical entity, and only 12 cases of Candida albicans prosthetic hip infection have been described. Although surgery combined with a long period of antifungal medication is the usual treatment for fungal prosthetic joint infections, monotherapy with antifungal agents has only very rarely been used as a therapeutic option, especially in debilitated and elderly patients. We report herein the second case, to our knowledge, of C. albicans prosthetic hip arthritis successfully treated with fluconazole monotherapy and review the literature on the pathogenesis, clinical manifestations and management of these infections. Further studies on the use of fluconazole in the management of fungal prosthetic infections are needed.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Fluconazol, ≥98% (HPLC), powder
Supelco
Fluconazol, Pharmaceutical Secondary Standard; Certified Reference Material
USP
Fluconazol, United States Pharmacopeia (USP) Reference Standard
Supelco
Fluconazol -Lösung, 2.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Fluconazol, European Pharmacopoeia (EP) Reference Standard
Fluconazol für die Peakidentifizierung, European Pharmacopoeia (EP) Reference Standard